News
Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...
Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...
GlobalData on MSN10h
Gilead’s Yeztugo sales “ahead of expectations” following launchGilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...
The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...
With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...
Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black women-serving organizations in the U.S. since 2010, with $28 million granted to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results